SHANGHAI – Last week the CFDA put out a circular to warn Chinese consumers about the dangers of buying cancer medicines online, in particular drugs that claim to be Iressa (gefitinib) imported from India.
SHANGHAI – China's distribution sector took a big step toward consolidation with the announcement that Sinopharm Group Co. Ltd and Shanghai Fosun Group Co. Ltd. would form a joint venture (JV) to create what promises to be the first nationwide drug and medical device network.
SHANGHAI – While Wuxi Apptec may be best known for its biologic manufacturing capabilities, it could be overlooked that the firm has ratcheted up its capabilities in clinical drug development as well.
SHANGHAI – Jiangsu Nhwa Pharmaceutical Co. Ltd.'s DP-VPA, a modified valproic acid (VPA) treatment for epilepsy, has received fast track status from the CFDA. The drug was first licensed from D-Pharm Ltd., of Rehovot, Israel, in 2011 and holds promise for its targeted technology to be more potent and safer than other forms of VPA, the leading therapy for seizures.
SHANGHAI – Jiangsu Nhwa Pharmaceutical Co. Ltd.'s DP-VPA, a modified valproic acid (VPA) treatment for epilepsy, has received fast track status from the CFDA.
SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd. released positive phase III data for apatinib at American Society of Clinical Oncology (ASCO) meeting last week and is now waiting for the good word from the CFDA for marketing approval in China. Apatinib, a molecular targeted therapy for the treatment of advanced gastric cancer has been shown to be associated with improved survival in patients with prior failure to second line chemotherapy.
SHANGHAI – It is no secret that China is heavy on generics and light on innovation. But what happens when a successful drug maker with deep pockets and a visionary chairman decide to take on drug discovery? Haiyan Pharmaceutical Technology Co. Ltd., the drug development subsidiary of the Yangtze River Pharmaceutical Group (YRP), and its team of executive returnees are set to prove that innovation can be implanted anywhere, even in a risk adverse generics maker.
SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd. released positive phase III data for apatinib at American Society of Clinical Oncology (ASCO) meeting last week and is now waiting for the good word from the CFDA for marketing approval in China. Apatinib, a molecular targeted therapy for the treatment of advanced gastric cancer has been shown to be associated with improved survival in patients with prior failure to second line chemotherapy.
SHANGHAI – Hutchinson China Meditech Ltd. (Chi-Med) has struck a new deal with its joint venture partner of 13 years, Shanghai Traditional Chinese Medicine Co. Ltd. (STCM), to exclusively sell six prescription drugs in China. Chi-Med's commercial operations help to fund its extensive R&D efforts with seven candidates in the clinic for oncology, immunology and inflammation.
SHANGHAI – Glaxosmithkline plc has confirmed the company is under investigation by the UK Serious Fraud Office (SFO). The case is presumed to be related to the almost year-long corruption investigation into GSK China activities that came to a close last week. UK's largest drugmaker is facing ever more serious legal troubles in its own backyard as the big pharma and its executives are awaiting trial here.
